Vivimed Labs Ltd

At Rs 7.02, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 3.14% on 7 May 2026, with buyers queuing and no sellers willing to part with shares.

Vivimed Labs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 5 May 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The micro-cap pharmaceutical company’s technical outlook has improved to mildly bullish, prompting a reassessment of its market stance, even as financial and valuation metrics remain under pressure.

Vivimed Labs Ltd has seen its investment rating downgraded from Sell to Strong Sell, reflecting deteriorating fundamentals and a shift in technical indicators. The company’s micro-cap status, combined with weak financial trends and bearish technical signals, has prompted analysts to revise their outlook, signalling caution for investors amid ongoing challenges.

Vivimed Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 24 April 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 26 April 2026, providing investors with the most up-to-date analysis.

At Rs 6.89, sellers were still queuing — but there were no buyers willing to take the other side. Vivimed Labs Ltd locked at its lower circuit of 5% on 22 Apr 2026, with unfilled sell orders and a frozen price.

At Rs 7.37, Vivimed Labs Ltd locked at its lower circuit of 5% on 20 Apr 2026, with unfilled sell orders and a frozen price. Sellers were lined up to exit, but buyers were absent, creating a supply glut that halted further declines.

At Rs 7.75, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 2.84% on 17 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 7.67, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 5% on 15 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Vivimed Labs Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 13 April 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The micro-cap pharmaceutical company’s stock price rose 4.9% on the day, reflecting renewed investor interest amid a challenging financial backdrop.

At Rs 7.36, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 4.99% on 10 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 7.01, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 4.94% on 9 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Vivimed Labs Ltd has been downgraded from a Sell to a Strong Sell rating as of 8 April 2026, reflecting deteriorating technical indicators, weak financial trends, poor valuation metrics, and declining quality scores. The micro-cap pharmaceutical company’s stock has struggled significantly over the past year, with a year-to-date return of -65.3% compared to the Sensex’s modest -9.0% decline, underscoring the challenges facing investors.

At Rs 6.68, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 4.87% on 8 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 6.37, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 4.94% on 7 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 6.07, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Vivimed Labs Ltd locked at its upper circuit of 4.84% on 6 Apr 2026, with buyers queuing and no sellers willing to part with shares.